HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Gabriel N Hortobagyi Selected Research

Adjuvant Chemotherapy

11/2010	Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
11/2010	Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
10/2008	Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.
6/2008	Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
11/2007	Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.
9/2007	Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
7/2006	Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
3/2006	Impact of a scientific presentation on community treatment patterns for primary breast cancer.
6/2004	The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
2/2004	Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research network!

Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:

1 year subscription, $490.00 USD

Request Bulk Institution License Details >>

Gabriel N Hortobagyi Research Topics

Disease

159	Breast Neoplasms (Breast Cancer) 01/2013 - 01/2002
105	Neoplasms (Cancer) 01/2013 - 01/2002
23	Neoplasm Metastasis (Metastasis) 08/2012 - 06/2002
14	Carcinoma (Carcinomatosis) 06/2007 - 05/2002
10	Disease Progression 09/2012 - 04/2002
5	Residual Neoplasm 02/2012 - 04/2004
4	Heart Failure 08/2011 - 11/2002
4	Inflammatory Breast Neoplasms 02/2011 - 02/2004
3	Neutropenia 01/2011 - 01/2003
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011 - 10/2002
3	Circulating Neoplastic Cells 05/2010 - 04/2009
2	Obesity 10/2012 - 09/2008
2	Fatigue 02/2012 - 02/2004
2	Pneumonia (Pneumonitis) 02/2012 - 11/2004
2	Noninfiltrating Intraductal Carcinoma (DCIS) 02/2012 - 09/2011
2	Lymphatic Diseases (Lymphadenopathy) 09/2011 - 04/2011
2	Infection 01/2011 - 10/2002
2	Ductal Carcinoma 12/2006 - 01/2005
2	Lobular Carcinoma 12/2006 - 01/2005
1	Peripheral Nervous System Diseases (PNS Diseases) 11/2012

Drug/Important Bio-Agent (IBA)

30	Estrogens (Estrogen)FDA Link 01/2013 - 10/2002
29	HormonesIBA 01/2013 - 10/2002
24	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2012 - 10/2002
23	Epidermal Growth Factor Receptor (EGF Receptor)IBA 01/2013 - 10/2002
23	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2011 - 04/2002
22	Paclitaxel (Taxol)FDA LinkGeneric 03/2012 - 05/2002
21	Fluorouracil (Carac)FDA LinkGeneric 03/2012 - 05/2002
19	taxaneIBA 06/2012 - 06/2002
19	trastuzumab (Herceptin)FDA Link 02/2012 - 04/2002
12	Progesterone Receptors (Progesterone Receptor)IBA 01/2013 - 10/2002
12	TaxoidsIBA 12/2011 - 05/2002
11	AnthracyclinesIBA 06/2012 - 09/2003
11	docetaxel (Taxotere)FDA Link 03/2012 - 04/2002
10	Tamoxifen FDA LinkGeneric 02/2012 - 01/2002
8	DNA (Deoxyribonucleic Acid)IBA 01/2013 - 01/2007
8	Phosphotransferases (Kinase)IBA 11/2010 - 05/2003
7	Messenger RNA (mRNA)IBA 03/2012 - 06/2005
7	Biological Markers (Surrogate Marker)IBA 02/2012 - 09/2003
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2012 - 08/2007
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2011 - 06/2003
6	Proteins (Proteins, Gene)IBA 01/2011 - 09/2003
5	capecitabine (Xeloda)FDA Link 03/2012 - 12/2008
5	Epirubicin (Ellence)FDA LinkGeneric 03/2012 - 06/2005
4	Transcription Factors (Transcription Factor)IBA 02/2012 - 09/2003
4	lapatinib (GW572016)FDA Link 09/2011 - 01/2010
4	bevacizumab FDA Link 08/2011 - 07/2010
4	Estrogen ReceptorsIBA 12/2006 - 05/2002
3	ParaffinIBA 01/2013 - 04/2004
3	ixabepilone (BMS 247550)FDA Link 11/2012 - 01/2011
3	everolimus FDA Link 02/2012 - 10/2007
3	Aromatase (CYP19)IBA 02/2012 - 03/2004
3	exemestane (Aromasin)FDA Link 02/2012 - 03/2004
3	Aromatase InhibitorsIBA 02/2012 - 02/2012
3	Selective Estrogen Receptor Modulators (SERM)IBA 02/2012 - 03/2004
3	anastrozole (Arimidex)FDA LinkGeneric 02/2012 - 01/2003
3	DiphosphonatesIBA 01/2012 - 05/2008
3	Leucovorin (Folinic Acid)FDA Link 05/2010 - 06/2004
3	Cadherins (E-Cadherin)IBA 05/2010 - 12/2006
3	Cyclin D1IBA 05/2010 - 10/2002
3	tau Proteins (tau Protein)IBA 09/2009 - 06/2005
2	Erythropoietin FDA Link 08/2011 - 11/2010
2	EndostatinsIBA 08/2011 - 01/2006
2	Cytosine DeaminaseIBA 08/2011 - 01/2006
2	gemcitabine FDA Link 01/2011 - 09/2003
2	Phenobarbital (Luminal)FDA Link 01/2011 - 05/2009
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2011 - 07/2003
2	Tyrosine (L-Tyrosine)FDA Link 01/2011 - 08/2007
2	CytotoxinsIBA 01/2011 - 01/2008
2	erlotinib (CP 358,774)FDA Link 01/2011 - 08/2007
2	Epidermal Growth Factor (EGF)IBA 11/2010 - 10/2007
2	Protein Kinases (Protein Kinase)IBA 11/2010 - 02/2004
2	Small Interfering RNA (siRNA)IBA 11/2010 - 05/2010
2	TegafurIBA 05/2010 - 03/2010
2	UracilIBA 05/2010 - 03/2010
2	thymidine 5'-triphosphate (TTP)IBA 05/2010 - 03/2010
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 05/2009 - 01/2008
2	CyclinsIBA 01/2009 - 10/2006
2	zoledronic acid (zoledronate)FDA Link 06/2008 - 01/2005
2	Dihydrotachysterol (AT 10)IBA 09/2007 - 10/2005
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2007 - 10/2002
2	Cyclin EIBA 01/2007 - 11/2002
2	P-GlycoproteinIBA 01/2007 - 08/2005
2	Methotrexate (Mexate)FDA LinkGeneric 06/2004 - 11/2003
2	Peptide Hydrolases (Proteases)IBA 03/2004 - 09/2003
2	Cell Adhesion MoleculesIBA 03/2004 - 09/2003
2	Telomerase (Telomerase Reverse Transcriptase)IBA 03/2004 - 09/2003
1	Stearoyl-CoA DesaturaseIBA 01/2013
1	Formaldehyde (Formol)FDA Link 01/2013
1	epothilone B (EPO906)IBA 11/2012
1	AngiozymeIBA 09/2012

Therapy/Procedure

91	Drug Therapy (Chemotherapy) 09/2012 - 01/2002
14	Adjuvant Chemotherapy 11/2010 - 05/2002
12	Radiotherapy 09/2011 - 06/2002
12	Mastectomy (Mammectomy) 09/2011 - 01/2002
10	Neoadjuvant Therapy 02/2012 - 10/2002
6	Heterologous Transplantation (Xenotransplantation) 10/2012 - 10/2002
3	Segmental Mastectomy (Lumpectomy) 10/2009 - 10/2002
2	Hematopoietic Stem Cell Transplantation 08/2011 - 11/2004
2	Combination Drug Therapy (Combination Chemotherapy) 05/2011 - 02/2006
2	Aftercare (After-Treatment) 10/2004 - 02/2004